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Increased arterial stiffness – similar findings in patients with inflammatory bowel disease 
without prior hypertension and diabetes and in patients with well-controlled hypertension 
Abstract: 
Purpose: Chronic inflammatory diseases are related with earlier onset of atherosclerosis. We hypothesized 
that inflammatory bowel disease patients with chronic, systemic inflammation have an increased arterial 
stiffness associated with the disease duration. Also, we wanted to compare arterial stiffness markers between 
inflammatory bowel disease and well-controlled hypertension patients.    
Materials and methods: A total of 89 inflammatory bowel disease patients (60 patients with Crohn’s disease  
and 29 patients with ulcerative colitis, age range 20-64 years) without history of arterial hypertension or 
diabetes were enrolled and age matched with a control group of patients (73 patients, age range 25-69 years, 
41 (56.1%) males) with known history of well-controlled arterial hypertension. We have used a noninvasive 
device that simultaneously measures brachial blood pressure and estimates PWV and AIx in inflammatory 
bowel disease and hypertension groups of patients.   
Results: Patients with pathological PWV values were significantly older, had significantly longer duration of 
inflammatory bowel disease, higher values of serum cholesterol and HDL-cholesterol, and higher AIx 
(17.4% vs. 9.8%) (all p<0.05). Higher PWV was associated with age and duration of inflammatory bowel 
disease in the linear regression model. PWV values were higher in hypertensive patients in the first two age 
quartiles while interestingly, in the last two quartiles, PWV was lower than in inflammatory bowel disease 
group of patients.   
Conclusions: Chronic subclinical inflammation is responsible for dyslipidemia and accelerated 
atherosclerosis which consequently alterates arterial elasticity. Inflammatory bowel disease and its duration 
should also be considered a risk factor for subclinical organ damage, as well as hypertension. 
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Introduction: 
Inflammatory bowel disease is a group of medical conditions characterized by chronic immunologic 
activation and inflammation of small and large intestine [1]. Higher risk of thromboembolic 
incidents in inflammatory bowel disease patients has been well researched [2] and found to be 
especially high during relapse and in chronically active disease [3]. Pivotal role of inflammation 
mechanisms in the development of atherosclerosis is undisputable and chronic inflammatory 
diseases are related with earlier onset of atherosclerosis [4–6]. Inflammatory bowel disease usually 
occurs in younger population in their second and third life decade. Taking latter into consideration, 
long-standing inflammation and a consequential development of atherosclerosis has a profound 
medical effect and impact on patient's quality of life [7]. Arterial stiffness is one of the indicators of 
vascular aging and has an important role in the cardiovascular disease. Measurement of arterial 
stiffness is used in every-day practice to assess the cardiovascular risk in patients [8,9]. Arterial 
stiffness depends on age and presence of established risk factors for atherosclerosis such as 
smoking, hypertension, diabetes and hyperlipidemia [10–14]. Arterial stiffness can be assessed 
noninvasively by measuring aortic pulse wave velocity (PWV) and augmentation index (AIx), 
which is shown to have predictive value for future fatal cardiovascular events and for determining 
cardiovascular risk in the population [15,16]. We hypothesized that inflammatory bowel disease 
patients with chronic, systemic inflammation have an increased arterial stiffness which is associated 
with the disease duration rather than the present disease activity. Furthermore, we wanted to 
evaluate possible difference in arterial stiffness markers, PWV and AIx, between inflammatory bowel 
disease patients and age and sex matched controls with well-controlled hypertension. The aim of this 
work was to study the arterial stiffness in relation to inflammatory bowel disease. 
 
Materials and methods: 
Study Patients 
A total of 89 inflammatory bowel disease patients (60 patients with Crohn’s disease and 29 patients 
with ulcerative colitis, age range 20-64 years) without history of arterial hypertension or diabetes 
were enrolled and age-matched with a control group of patients (73 patients, age range 25-69 years, 
41 (56.1%) males) with known history of well-controlled arterial hypertension. All of the patients in 
the control group were using antihypertensive medications (ACE-inhibitors, angiotensin II receptor 
blockers or calcium channel blockers) with no differences in number of antihypertensives per 
patient and in number of different antihypertensive classes between subgroups of patients divided 
by age quartiles. All of hypertensive patients had well controlled hypertension. There was no 
difference between the duration of the inflammatory bowel disease and hypertension in the two groups 
(122.0+10.2 vs 131.2+11.1 months). Hypertension in inflammatory bowel disease patients was 
defined as blood pressure levels ≥140/90 mmHg. Exclusion criteria were: amputees, history of 
mental illness, atrial fibrillation or other chronic arrhythmias, stage III-IV congestive heart failure, 
liver disease or ascites, diabetes, history of stroke, transient ishemic attack (TIA), myocardial 
infarction (in the three previous months) or malignant disease. The protocol was approved by the 
hospital ethics committee, in accordance with the Helsinki Declaration, and all participants gave 
written informed consent.  
Data Collection 
The detailed medical history of the patients was collected and a complete physical examination was 
conducted. In all patients following biochemical data were collected: complete blood count (CBC), 
C-reactive protein, fibrinogen, serum glucose, lipid profile, sodium, potassium, calcium, 
phosphorus, blood urea nitrogen (BUN) and creatinine, bilirubin, liver transaminases, gamma-
glutamyl transferase (γGT)  
alkaline phosphatase, hemoglobin A1c (HbA1c). The activity of Crohn's disease was assessed by 
Harvey-Bradshaw index while the severity of ulcerative colitis was assessed by Truelove and Witts’ 
criteria. Target organ damage of the kidneys was determined by measuring creatinine clearance and 
microalbuminuria in the 24-hour urine sample.  
Hamodynamic measurement 
The noninvasive measurement of pulse wave velocity, as an index of arterial stiffness, was 
performed in inflammatory bowel disease group and hypertension group of patients using previously 
validated, noninvasive device (Tensiomed Arteriograph device (Medexpert Ltd., Budapest, 
Hungary)), that uses oscillometric method which simultaneously measures brachial blood pressure, 
PWV and AIx. Measurement was done in a dedicated room in a recumbent position after the 15 
minutes rest. PWV and AIx were determined as a mean of three measurements. PWV is low in 
arteries of normal elasticity and increases in the stiffer (and older) arteries. Recent study reported a 
mean PWV of 7.8±2.2 m/s in patients with systemic lupus which is a similar disease to inflammatory 
bowel disease in terms of chronic inflammation and its association with advanced atherosclerosis so 
we have divided inflammatory bowel disease patients in quartiles depending on different PWV values 
[17].  
Statistical analysis  
It was performed using SPSS version 23.0 (IBM Corp., USA). Normality of data distribution was 
tested using Kolmogorov-Smirnov test. Preliminary analyses were performed to ensure no violation 
of the assumptions of normality, linearity and homoscedasticity. Categorical data were expressed as 
numbers and frequencies. Correlations were obtained using Pearson's test for normally distributed 
variables and Spearman rank correlation for non-normally distributed variables. Normally 
distributed variables were presented as means + standard deviations and Student’s t test for 
independent samples was used for comparisons between two groups. Non-normally distributed data 
was presented as median and interquartile range and Mann-Whitney U-test was used in comparison 
between two groups. Categorical variables were compared using χ2- test. Analysis of variance 
(ANOVA) was used to detect significant differences among ≥ two groups. Binary logistic regression 
was made to assess prediction of elevated PWV levels. Multiple linear regression was used to 
explore the influence of different variables on PWV levels. A p value <0.05 (two-sided tests) was 
considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Results: 
We have enrolled 89 patients (age 34 (20-64); men 52/58.4%). There were no differences in age, 
gender and smoking status between inflammatory bowel disease patients with Crohn's disease and 
ulcerative colitis. The differences in duration of inflammatory bowel disease and biochemical data as 
well as in blood pressure values and arterial stiffness markers AIx and PWV were not found 
between these two groups of patients. Importantly, significantly higher number of Crohn's disease 
patients was on immunosuppressant and biologic treatment compared with ulcerative colitis 
patients. However, when the patients on immunosuppressive and biologic treatment were compared 
with patients without imunosuppressive and biologic treatment no significant difference in arterial 
stiffness markers was found. Additionally, we have not found any differences when patients were 
divided by gender. The patients were divided by the localization of ulcerative colitis, proctitis, left-
sided colitis and pancolitis, and although the duration of inflammatory bowel disease was significantly 
longer in patients with pancolitis we have not found differences in hemodynamic parameters. We 
have failed to find any differences in patients with different Crohn's disease phenotypes and 
differences in hemodynamic parameters between patients with different disease activity. 
Demographic, clinical and biochemical data of inflammatory bowel disease patients are shown in 
Table 3. (online supplement). Hemodynamic characteristics of inflammatory bowel disease patients 
are shown in Table 4. (online supplement).  
We have divided patients in quartiles depending on different PWV values. Patients in last two 
quartiles were significantly older than patients in first two quartiles with no differences in duration 
of inflammatory bowel disease. Patients in the last quartile had higher values of systolic, diastolic and 
central systolic blood pressure than patients in the first three quartiles while AIx values were higher 
than in patients in the first two quartiles (Table 2. online supplement). On univariate analysis PWV 
was positively correlated with age (r=0.495; p<0.001), duration of inflammatory bowel disease 
(r=0.236; p=0.03), central systolic blood pressure (r=0.478, p<0.001), serum cholesterol (r=0.304, 
p=0.005), LDL-cholesterol (r=0.277, p=0.01) and HDL-cholesterol (r=0.241, p=0.03) while AIx 
was positively correlated with age (r=0.563; p<0.001), duration of inflammatory bowel disease 
(r=0.283; p<0.01), central systolic blood pressure (r=0.352, p=0.001), serum cholesterol (r=0.375, 
p=0.001), LDL-cholesterol (r=0.346, p=0.01) and HDL-cholesterol (r=0.272, p=0.01). On logistic 
regression older patients, patients with longer duration of inflammatory bowel disease and patients 
with higher values of LDL-cholesterol had OR´s for PWV>8 m/s of 4.64 [CI 1.01, 1.14], 7.55 [CI 
1.00, 1.01] and 4.73 [CI 1.19, 26.8]. In the linear regression model age and duration of inflammatory 
bowel disease were only and positive predictors of higher PWV (β= 0.452 and β=0.363, all p<0.05) 
while we have not found this association with dyslipidemia.   
In all group of patients there were 11.2% (10/89) inflammatory bowel disease patients with newly-
diagnosed hypertension. Hypertensive inflammatory bowel disease patients had significantly higher 
PWV values when compared to non-hypertensive patients (9.3 vs. 7.6 m/s; p<0.003). We have 
failed to find any differences in other variables when comparing these two subgroups of patients 
except longer duration of inflammatory bowel disease in hypertensive patients although statistically 
insignificant (146.0 vs. 118.9 months). When AIx and PWV were compared between inflammatory 
bowel disease patients and well controlled hypertensive patients by age quartiles we have found 
higher AIx values in hypertensive patients in the first two age quartiles while there were no 
differences between two groups in the last two quartiles (Table 1). There were no differences in 
PWV values between these two groups of patients except in the last quartile where interestingly 
PWV was higher in inflammatory bowel disease group of patients. Hypertensive patients had higher 
central systolic blood and pulse pressure values in the second and third quartile. We have found in 
the last two quartiles significantly higher total and LDL-cholesterol levels in inflammatory bowel 
disease group. Duration of hypertension and inflammatory bowel disease were similarly correlated 
with higher PWV levels (Figure 1). 
 
Discussion: 
Increased arterial stiffness is well known marker of subclinical target organ damage and it is 
strongly and independently associated with increased cardiovascular morbidity and mortality [8,15]. 
Chronic inflammatory diseases like systemic lupus, vasculitis and rheumatoid arthritis progressively 
lead to stiffening of large arteries through presence of atherosclerosis and longer duration of the 
underlying chronic inflammatory disease [5]. Inflammatory bowel disease is associated in many 
reports with premature atherosclerosis caused by endothelial dysfunction and increased intima-
media [18,19]. The prevalence of hypertension, diabetes and dyslipidemia in inflammatory bowel 
disease is lower when compared to general population, however, cardiovascular risk is increased 
[20,21]. In many studies one of the possible explanations for this paradox is an increased PWV, 
which is an independent marker for increased cardiovascular risk in inflammatory bowel disease 
patients when compared to general population [22–24]. Various risk factors contribute to increased 
arterial stiffness in inflammatory bowel disease. Beside different therapy, biologic treatment, 
immunosuppression and corticosteroids, BMI, cytokine levels and C-reactive protein, the duration 
of inflammatory bowel disease was reported to have a very important association with increased PWV 
levels [16].   
In the last two PWV quartiles, more advanced chronological aging and increased vascular aging as 
a result of prolonged duration of inflammatory bowel disease are the most plausible explanations for 
pathological PWV. Interestingly, these patients had not only increased arterial stiffness of large 
arteries but also AIx. In contrast to previous reports [25], we have not found associations between 
active disease and increased arterial stiffness but only the duration of the disease as a marker of 
prolonged inflammation independent of already established risk factors which is similar to the 
meta-analysis by Zanoli et al [26]. Different Crohn's disease phenotypes and ulcerative colitis 
localization were not associated with increased PWV. Microalbuminuria and left ventricular 
hypertrophy as markers of target organ damage were almost not present while increased PWV was 
present in 40.4% of all inflammatory bowel disease patients. Regarding these results PWV in 
inflammatory bowel disease patients should be measured more often as a risk factor for development 
of cardiovascular disease. In all groups of patients, age, duration of inflammatory bowel disease and 
dyslipidemia were strong and independent predictors of both increased arterial stiffness markers, 
PWV and AIx, while interestingly, activity of inflammatory bowel disease, biologic treatment and 
immunosuppression were not significant predictors at all.   
This is the first study, at least to our knowledge, which analyzed and made a comparison of arterial 
stiffness markers between patients with inflammatory bowel disease and hypertensive patients with 
already established risk factor for increased arterial stiffness. In all groups of patients we have not 
found differences in PWV values between patients with inflammatory bowel disease and matched 
controls with hypertension while hypertensives had higher AIx values. Interestingly, when patients 
were divided by age quartiles, inflammatory bowel disease patients had higher PWV values in the last 
two quartiles with no differences in AIx values. This is confirming our presumption that 
inflammatory bowel disease and its longevity plays a similar role as hypertension, an already 
established risk factor, for increased arterial stiffness (Figure 1). Furthermore, the presence of 
dyslipidemia in these last two inflammatory bowel disease patients group quartiles is an additional 
risk factor for increased arterial stiffness. Age and blood pressure values must be taken into account 
analyzing arterial stiffness especially in the reference range. Some subjects are at higher risk than 
others although in the same age group even when PWV is below a cut-off for pathological values. 
Large study by Mattace-Raso et al. [27] have obtained data of PWV and basic clinical parameters 
on 1455 patients with optimal blood pressure values from eight European countries and tried to 
establish normal and reference values of PWV. All age quartiles of inflammatory bowel disease 
patients from our study had higher PWV in comparison with these reference values as well as with 
the results from other studies [27–29]. Our results are in line with previous studies which reported 
higher PWV values in inflammatory bowel disease patients when compared to general population 
[22–24]. The association of longer duration of inflammatory bowel disease and pathological PWV 
was stronger than with dyslipidemia and age since older inflammatory bowel disease patients had 
higher arterial stiffness markers than hypertensive patients. In the light of these results it can be 
presumed that arterial stiffness and vascular aging are more pronounced in inflammatory bowel 
disease patients with longer disease duration compared, not only to healthy controls, but to patients 
with already established risk factors such as hypertension as well.  
Increased arterial stiffness is a well-known characteristic of inflammatory bowel disease patients. Our 
results on higher PWV and AIx in patients with longer duration of inflammatory bowel disease are in 
line with our hypothesis that chronic inflammation, regardless of disease activity, is responsible for 
wall alterations of both large and smaller arteries. Premature atherosclerosis and the presence of 
dyslipidemia as determinants of increased PWV should be strongly monitored and aggressively 
corrected especially in patients with longer inflammatory bowel disease duration. This is the first 
study which analyzed not only arterial stiffness in inflammatory bowel disease patients but also 
compared its values with hypertensive patients. In this cross-sectional study we confirmed our 
hypothesis and found that arterial stiffness markers in inflammatory bowel disease patients with 
longer disease duration were higher than in hypertensive patients.   
Our work has several limitations. First, we have enrolled patients from only one inflammatory bowel 
disease center and our results should be confirmed on larger number of patients. Secondly, although 
we have analyzed only hypertensives without diabetes and with the same classes of 
antihypertensive drugs, the markers of inflammation were not analyzed in this matched control 
group. Therefore, we could not see possible differences in unknown inflammation status between 
these patients. Thirdly, unfortunately carotid intima media thickness as an additional marker of 
subclinical organ damage was not analyzed which would additionally improve obtained results. 
Fourth, we did not analyze possible differences in arterial stiffness markers over time. One could 
argue that in this study we have seen a strong and independent association of disease duration and 
increased arterial stiffness but possible increase of arterial stiffness in younger patients over time 
could be an additional proof for this association. Fifth, the data for future cardiovascular incidents 
and mortality in this group of patients would be of extreme importance in determining inflammatory 
bowel disease duration not only as a marker for increased arterial stiffness but also as a marker for 
future cardiovascular events. Sixth, PWV was determined using Arteriograph, device which is 
validated but with no referral cut-off values for inflammatory bowel disease patients. Seventh, 
although this is the first study which analyzed and compared arterial stiffness between inflammatory 
bowel disease and hypertensive patients the lack of healthy control group is a limitation factor for 
this study.  
Increased arterial stiffness in inflammatory bowel disease patients is associated with longer disease 
duration, but not with disease activity. Chronic subclinical inflammation is responsible for 
dyslipidemia and accelerated atherosclerosis which consequently alterates arterial elasticity. 
inflammatory bowel disease and its duration should also be considered a risk factor for subclinical 
organ damage, as well as hypertension. These patients should be monitored very carefully and in 
larger number for risk stratification for future fatal cardiovascular events.            
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Figure 1. Scatter-plot on inflammatory bowel disease and chronic hypertension duration correlation 
with pulse wave velocity 
 
Inflammatory bowel disease – dark filled circles and full line; Hypertension – white squares and dashed line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Differences in demographic, clinical, biochemical and hemodynamic data between 
inflammatory bowel disease and hypertension patients by age  
Age Quartiles 
 
1 
 Years (18-26) 
2 
Years (27-38) 
3 
Years (39-52) 
4 
Years (53-69) 
Inflammatory 
bowel disease 
(N=22) 
Hypertension 
(N=18) 
Inflammatory 
bowel disease 
(N=21) 
Hypertension 
(N=17) 
Inflammatory 
bowel disease 
(N=24) 
Hypertension 
(N=19) 
Inflammatory 
bowel disease 
(N=22) 
Hypertension 
(N=19) 
Males (N/%) 14 (63.6) 10 (55.5) 13 (61.9) 9 (52.9) 14 (58.3) 12 (63.2) 11 (50.0) 10 (52.6) 
Smoker (N/%) 1 (4.5) 1 (5.5) 2 (9.5) 2 (11.7) 2 (8.3) 2 (10.5) 2 (9.1) 3 (15.8) 
Duration of  
bowel disease 
or 
hypertension 
(months) 
74.0±5.8 102.7±16.3 116.6.±17.4 144.7±21.2 135.7±18.9^ 79.4±6.9 232.0±35.1 145.3±21.9 
Serum 
cholesterol 
(mmol/L) 
3.07±0.4 2.99±0.3 3.07±0.4 3.01±0.3 4.35±0.5* 3.31±0.4 4.08±0.5° 3.45±0.4 
HDL-
cholesterol 
(mmol/L) 
0.98±0.2 0.95±0.2 1.06±0.2 0.99±0.2 1.21±0.2 1.05±0.2 1.26±0.2 1.15±0.2 
LDL-
cholesterol 
(mmol/L) 
1.47±0.3 1.44±0.3 1.55±0.3 1.51±0.3 2.42±0.3° 1.72±0.3 2.92±0.3° 2.13±0.3 
Serum 
triglycerides 
(mmol/L) 
1.15±0.2 1.19±0.2 0.96±0.2 1.05±0.2 1.46±0.2 1.33±0.2 1.29±0.2 1.33±0.2 
Systolic blood 
pressure 
(mmHg) 
124.5±14.4 125.7±15.3 121.0±14.1 135.7±16.2^ 122.7±16.2 135.9±16.8^ 129.9±16.2 143.6±18.3 
Diastolic 
blood pressure 
(mmHg) 
71.7±8.8 72.2±9.0 69.9±8.1 78.8±9.5^ 74.2±9.1 77.3±9.9 78.3±11.6 84.7±11.1 
Heart rate 
(b/pm) 76 (57-102) 79 (58-103) 71 (53-100) 71 (54-101) 71 (54-100) 77 (58-103) 71 (53-101) 67 (52-98) 
Central 
systolic blood 
pressure 
(mmHg) 
109.9±12.4 113.5±13.2 106.3±11.7 121.8±14.0° 114.6±13.8 131.1±18.2° 125.3±14.7 139.2±18.8 
Central pulse 
pressure 
(mmHg) 
52.8±5.8 53.5±5.9 51.1±5.3 58.9±6.3^ 48.5±4.8 58.6±6.3° 51.6±5.5 58.8±6.4 
Augmentation 
index 
(%) 
6.8±1.7 14.0±3.5^ 6.4±1.4 24.3±5.2* 19.3±4.4 24.6±5.4 27.6±6.2 27.8±6.5 
Pulse wave 
velocity 
(m/s) 
7.1±1.5 7.5±1.7 7.1±1.6 7.7±2.0 8.3±2.1 8.1±1.9 9.7±2.8° 8.1±1.8 
results are shown as mean +/- SD or median (interquartile range) 
* - p<0.001; ° -  p<0.01; ^ - p<0.05 
 
